siRNA therapy decreases triglycerides in patients along with uncommon problem

.RESEARCH STUDY HIGHLIGHT.19 September 2024.

Plozasiran minimized triglyceride levels by 80% and reduced the risk of pancreatitis in patients along with consistent chylomicronemia, with or without a hereditary prognosis.